The October 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
As of the most recently reported period, short sellers still favored Microsoft, Intel and Pfizer above all other Dow stocks.
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck and Pfizer.
The September 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
As of the most recently reported period, short sellers favored Microsoft, Intel and Pfizer above all other Dow stocks.
The last thing investors want is a value trap loser that stays stagnant, but all these top companies have solid long-term prospects.
Pfizer has announced positive top-line results from a second Phase 3 pivotal study evaluating abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis.
Chris Lange The September 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
As of the most recently reported period, short sellers favored Pfizer, Intel and Microsoft above all other Dow stocks.
The August 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
As of the most recently reported period, short sellers favored Pfizer, Intel and Microsoft above all other Dow stocks.
The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
As of the most recently reported period, short sellers favored Intel, Pfizer and Microsoft above all other Dow stocks.
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
